Drug Search Results
More Filters [+]

GSK-2256294

Alternative Names: gsk-2256294, gsk2256294, gsk 2256294
Latest Update: 2023-11-15
Latest Update Note: PubMed Publication

Product Description

GSK-2256294 is a potent, reversible, tight binding inhibitor of isolated recombinant human sEH (soluble epoxide hydrolase) (IC50 = 27 pM; t1/2 = 121 min) and displays potent inhibition against the rat (IC50 = 61 pM) and murine (IC50 = 189 pM) orthologs of sEH. (Sourced from: https://drugs.ncats.io/substance/L33EX3XR0T)

Mechanisms of Action: EPHX Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GSK-2256294

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Intracranial Aneurysm|Vasospasm, Intracranial|Subarachnoid Hemorrhage|Cerebral Hemorrhage|Brain Infarction|Ischemic Stroke|Obesity|Prediabetes|Glucose Metabolism Disorders

Phase 1: Chronic Obstructive Pulmonary Disease|Hypoxia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

5R01DK117875

P2

Completed

Obesity|Prediabetes|Glucose Metabolism Disorders

2021-11-18

SUSHI

P2

Completed

Cerebral Hemorrhage|Brain Infarction|Vasospasm, Intracranial|Intracranial Aneurysm|Subarachnoid Hemorrhage|Ischemic Stroke

2019-04-03

NCT02262689

P1

Completed

Chronic Obstructive Pulmonary Disease|Hypoxia

2015-04-24

NCT02006537

P1

Completed

Chronic Obstructive Pulmonary Disease

2014-05-27

Recent News Events